363 related articles for article (PubMed ID: 28059452)
1. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
Cheng Z; Lei Z; Yang P; Si A; Xiang D; Zhou J; Hüser N
Gene; 2019 Feb; 684():95-103. PubMed ID: 30359743
[TBL] [Abstract][Full Text] [Related]
3. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
[TBL] [Abstract][Full Text] [Related]
4. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling.
Liu F; Wu X; Jiang X; Qian Y; Gao J
J Exp Clin Cancer Res; 2018 Jun; 37(1):122. PubMed ID: 29940988
[TBL] [Abstract][Full Text] [Related]
5. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
Li B; Liu D; Yang P; Li HY; Wang D
Gene; 2019 Jul; 707():78-85. PubMed ID: 31075412
[TBL] [Abstract][Full Text] [Related]
6. Zinc finger protein X-linked promotes expansion of EpCAM
Wang C; Fu SY; Wang MD; Yu WB; Cui QS; Wang HR; Huang H; Dong W; Zhang WW; Li PP; Lin C; Pan ZY; Yang Y; Wu MC; Zhou WP
Mol Oncol; 2017 May; 11(5):455-469. PubMed ID: 28156061
[TBL] [Abstract][Full Text] [Related]
7. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
8. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.
Liu C; Li J; Wang W; Zhong X; Xu F; Lu J
Cell Cycle; 2020 May; 19(10):1077-1088. PubMed ID: 32286127
[TBL] [Abstract][Full Text] [Related]
9. Enrichment of cancer stem cells via β-catenin contributing to the tumorigenesis of hepatocellular carcinoma.
Pandit H; Li Y; Li X; Zhang W; Li S; Martin RCG
BMC Cancer; 2018 Aug; 18(1):783. PubMed ID: 30075764
[TBL] [Abstract][Full Text] [Related]
10. PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.
Li M; Mu XD; Song JR; Zhai PT; Cheng Y; Le Y; Li ZB
Cell Cycle; 2021 May; 20(10):1010-1020. PubMed ID: 33970778
[TBL] [Abstract][Full Text] [Related]
11. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway.
Ran RZ; Chen J; Cui LJ; Lin XL; Fan MM; Cong ZZ; Zhang H; Tan WF; Zhang GQ; Zhang YJ
Exp Cell Res; 2019 May; 378(1):66-75. PubMed ID: 30844391
[TBL] [Abstract][Full Text] [Related]
12. miR-365 regulates liver cancer stem cells via RAC1 pathway.
Jiang ZB; Ma BQ; Liu SG; Li J; Yang GM; Hou YB; Si RH; Gao P; Yan HT
Mol Carcinog; 2019 Jan; 58(1):55-65. PubMed ID: 30182377
[TBL] [Abstract][Full Text] [Related]
13. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
14. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
[TBL] [Abstract][Full Text] [Related]
15. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
16. RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.
Chua HH; Tsuei DJ; Lee PH; Jeng YM; Lu J; Wu JF; Su DS; Chen YH; Chien CS; Kao PC; Lee CN; Hu RH; Ni YH; Chang MH
Hepatology; 2015 Nov; 62(5):1480-96. PubMed ID: 26185016
[TBL] [Abstract][Full Text] [Related]
17. lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal.
Zhu P; Wang Y; Huang G; Ye B; Liu B; Wu J; Du Y; He L; Fan Z
Nat Struct Mol Biol; 2016 Jul; 23(7):631-9. PubMed ID: 27239797
[TBL] [Abstract][Full Text] [Related]
18. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling.
Fan Z; Duan J; Wang L; Xiao S; Li L; Yan X; Yao W; Wu L; Zhang S; Zhang Y; Li Y; Zhu X; Hu Y; Zhang D; Jiao S; Xu X
Cancer Lett; 2019 May; 450():132-143. PubMed ID: 30849480
[TBL] [Abstract][Full Text] [Related]
19. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.
Xu Q; Xu HX; Li JP; Wang S; Fu Z; Jia J; Wang L; Zhu ZF; Lu R; Yao Z
Oncotarget; 2017 Mar; 8(10):16972-16987. PubMed ID: 28199981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
